News

A rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR) — resulted in early, progressive neurological…

Alnylam Pharmaceuticals is supporting two initiatives aiming to transform transthyretin amyloid cardiomyopathy (ATTR-CM) management, with a focus on earlier diagnosis and more coordinated…

A blood test commonly used to help diagnose Alzheimer’s disease may also identify people with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), characterized by damage…

Women with transthyretin amyloid cardiomyopathy (ATTR-CM) show differences in disease features and greater physical limitations than men, but are less likely to be given…

Six months of treatment with Amvuttra (vutrisiran) appears to maintain or slightly improve clinical status and quality of life among adults with hereditary…

Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help identify which patients with wild-type…

Hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) was a common clinical manifestation among people carrying a mutation in the TTR gene called p.Ala117Ser, according to…

The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate,…

Homes and landmarks across the U.S. and other countries will once again light up in red throughout March for Amyloidosis Awareness Month as the…

Signs of more advanced heart disease and the presence of nerve involvement are associated with a higher risk of worse outcomes, including heart failure, hospitalization…